Founded in 2019 and headquartered in Roscoff, SeaBeLife engineers dual-acting small molecules designed to block both necroptosis and ferroptosis, two regulated cell-death pathways that drive tissue damage in several acute and chronic diseases. Its lead candidates are SBL03 for dry age-related macular degeneration (with recent positive in-vivo data in geographic atrophy) and SBL01 for severe acute hepatitis, both addressing large unmet medical needs. The company plans to begin first-in-human clinical trials in 2026. SeaBeLife’s pipeline is positioned as a potentially transformative, first-in-class approach to organ protection, differentiating it from single-pathway competitors. To date, the firm has attracted €9 million in total funding through a mix of equity and public grants, including support from Bpifrance, SATT Ouest Valorisation, Biotech Santé Bretagne, and the Région Bretagne. The new capital strengthens its runway as the team prepares for a larger Series A round to finance clinical studies and expand development of its multi-target platform.

Total raised

$7M

Funding rounds

4

Latest round

Series A

Latest activity

Oct 2025